Investment Thesis
Elicio is a pre-revenue biotech with negative stockholders equity (-1.4M), annual operating burn of -11.6M, and estimated runway of ~1.3 years at current cash burn rates. Despite modest YoY loss improvement, the company's balance sheet is technically insolvent with liabilities exceeding assets, creating substantial financial distress risk without successful near-term clinical advancement or capital infusion.
Strengths
- Net loss improving 23.8% YoY, indicating potential path toward profitability milestone
- Adequate short-term liquidity with current ratio of 2.24x and cash position of 14.9M
- Minimal capital expenditure requirements (16K) typical of asset-light biotech model
Risks
- Negative stockholders equity of -1.4M indicates technical insolvency; liabilities exceed assets by 1.4M
- Zero revenue with no commercialized products; company entirely dependent on clinical/regulatory success
- Annual free cash burn of -11.7M depletes cash runway to ~1.3 years; requires external funding or revenue generation
Key Metrics to Watch
- Clinical trial progression and FDA regulatory milestones for lead candidates
- Quarterly cash burn rate and remaining cash runway duration
- Stockholders equity trajectory and path to positive equity position
Financial Metrics
Revenue
0.0
Net Income
-11.8M
EPS (Diluted)
$-0.65
Free Cash Flow
-11.7M
Total Assets
22.7M
Cash
14.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-52.1%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
2.24x
Quick Ratio
2.24x
Debt/Equity
N/A
Debt/Assets
106.3%
Interest Coverage
-294.50x
Long-term Debt
9.5M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T08:14:20.687432 |
Data as of: 2026-03-31 |
Powered by Claude AI